Gilead aims to cash in on liver disease wave with $4.6bn CymaBay deal
Gilead announced its $4.6bn acquisition of CymaBay will see it gain an advanced primary biliary cholangitis (PBC) candidate, as it aims to follow the success of Ocaliva.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
